Syngle Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Syngle Therapeutics is an early-stage biotech developing a novel gene therapy-based immunotherapy for Parkinson's disease, targeting toxic alpha-synuclein oligomers. Its lead asset, antibody 26F1, is in preclinical development and is protected by a patent application. The company was founded as a spin-out from Crossbeta Biosciences, has received grant support from The Michael J. Fox Foundation, and is led by a team with deep experience in gene therapy, neurodegeneration, and biotech finance. Syngle aims to address a significant unmet need for a disease-modifying treatment in a large and growing neurodegenerative market.

Parkinson's DiseaseSynucleinopathies

Technology Platform

Proprietary antibodies specific for oligomeric alpha-synuclein, delivered via a one-time AAV-mediated gene therapy to enable sustained intracranial antibody production.

Opportunities

The primary opportunity is addressing the vast unmet need for a disease-modifying therapy in Parkinson's disease, a market with over 10 million patients globally.

Success with its lead program could also enable expansion into other synucleinopathies like Dementia with Lewy Bodies and Multiple System Atrophy, leveraging the same platform technology.

Risk Factors

Key risks include the high failure rate of neurodegenerative disease trials, the unproven clinical validity of targeting alpha-synuclein oligomers for disease modification, and the technical and safety challenges associated with CNS gene therapy.

The company also faces intense competition from larger players and is dependent on raising significant capital to advance its costly development program.

Competitive Landscape

Syngle operates in the highly competitive field of alpha-synuclein-targeting therapies for Parkinson's. Major players like Biogen, Roche, and UCB have monoclonal antibody programs in clinical trials, though these typically require repeated intravenous infusion. Syngle's key differentiation is its oligomer-specific antibody combined with a one-time gene therapy delivery, aiming for sustained brain exposure, which sets it apart from most conventional antibody approaches.

More companies in Immunotherapy / Immuno-Oncology →More companies in Netherlands →